Rhinomed Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.
|Primary activities||The licensing, distribution and/or manufacturing of pharmaceutical and healthcare products.|
|Industry / Sector||Medical Devices / Healthcare|
|Mailing address||132 Gwynne Street Level 1 Cremorne VIC 3121 Australia|
|Phone / Fax||61 3 8416 0900 / 61 3 8080 0796|
|Share registry||AUTOMIC REGISTRY SERVICES|
Rhinomed paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.RNO dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
RNO's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of Aug 2022, following are the company executives and directors listed on Rhinomed.
|Mr. Michael Johnson||CEO, MD & Exec. Director||448.63k|
|Mr. Sean Slattery||CFO & Company Sec.||336.38k|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Rhinomed is and its enterprise value is .
The RNO's stocks Beta value is 1.05 making it 5% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Rhinomed (RNO)
Rhinomed (ASX:RNO) Frequently Asked Questions
1. What is Rhinomed's Stock Symbol?
Rhinomed trades on ASX under the ticker symbol "RNO".
2. What is Rhinomed's stock price today?
One share of RNO stock can currently be purchased for approximately $0.185.
3. How can I contact Rhinomed?
Rhinomed's mailing address is 132 Gwynne Street Level 1 Cremorne VIC 3121 Australia. The company can be reached via phone at 61 3 8416 0900.
4. What is Rhinomed's official website?
The official website of Rhinomed is https://www.rhinomed.global.
5. Which share registry manages Rhinomed's stock?
Rhinomed's stock is managed by AUTOMIC REGISTRY SERVICES.